Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M. Folegatti, Alexander Batten, Mustapha Bittaye et al.|The Lancet|2020Cited by 2.6k
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Malcolm G. Semple, Jiandong Huo et al.|Cell|2022Cited by 1k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie Ewer, Megan Baker, Jordan R. Barrett et al.|Nature Medicine|2020Cited by 643
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R. Barrett, Catherine Green, Sandra Belij‐Rammerstorfer et al.|Nature Medicine|2020Cited by 340